These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 34139154)

  • 21. Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death.
    Gisby J; Clarke CL; Medjeral-Thomas N; Malik TH; Papadaki A; Mortimer PM; Buang NB; Lewis S; Pereira M; Toulza F; Fagnano E; Mawhin MA; Dutton EE; Tapeng L; Richard AC; Kirk PD; Behmoaras J; Sandhu E; McAdoo SP; Prendecki MF; Pickering MC; Botto M; Willicombe M; Thomas DC; Peters JE
    Elife; 2021 Mar; 10():. PubMed ID: 33704068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach.
    Kimura Y; Nakai Y; Shin J; Hara M; Takeda Y; Kubo S; Jeremiah SS; Ino Y; Akiyama T; Moriyama K; Sakai K; Saji R; Nishii M; Kitamura H; Murohashi K; Yamamoto K; Kaneko T; Takeuchi I; Hagiwara E; Ogura T; Hasegawa H; Tamura T; Yamanaka T; Ryo A
    Sci Rep; 2021 Oct; 11(1):20638. PubMed ID: 34667241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers.
    Vázquez-Jiménez A; Avila-Ponce De León UE; Matadamas-Guzman M; Muciño-Olmos EA; Martínez-López YE; Escobedo-Tapia T; Resendis-Antonio O
    Front Immunol; 2021; 12():705646. PubMed ID: 34603282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
    ;
    Cell; 2022 Mar; 185(5):916-938.e58. PubMed ID: 35216673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.
    Shcherbak SG; Anisenkova AY; Mosenko SV; Glotov OS; Chernov AN; Apalko SV; Urazov SP; Garbuzov EY; Khobotnikov DN; Klitsenko OA; Minina EM; Asaulenko ZP
    Front Immunol; 2021; 12():745515. PubMed ID: 34858403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study.
    Byeon SK; Madugundu AK; Garapati K; Ramarajan MG; Saraswat M; Kumar-M P; Hughes T; Shah R; Patnaik MM; Chia N; Ashrafzadeh-Kian S; Yao JD; Pritt BS; Cattaneo R; Salama ME; Zenka RM; Kipp BR; Grebe SKG; Singh RJ; Sadighi Akha AA; Algeciras-Schimnich A; Dasari S; Olson JE; Walsh JR; Venkatakrishnan AJ; Jenkinson G; O'Horo JC; Badley AD; Pandey A
    Lancet Digit Health; 2022 Sep; 4(9):e632-e645. PubMed ID: 35835712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benchmarking of Machine Learning classifiers on plasma proteomic for COVID-19 severity prediction through interpretable artificial intelligence.
    Dimitsaki S; Gavriilidis GI; Dimitriadis VK; Natsiavas P
    Artif Intell Med; 2023 Mar; 137():102490. PubMed ID: 36868685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection.
    Captur G; Moon JC; Topriceanu CC; Joy G; Swadling L; Hallqvist J; Doykov I; Patel N; Spiewak J; Baldwin T; Hamblin M; Menacho K; Fontana M; Treibel TA; Manisty C; O'Brien B; Gibbons JM; Pade C; Brooks T; Altmann DM; Boyton RJ; McKnight Á; Maini MK; Noursadeghi M; Mills K; Heywood WE;
    EBioMedicine; 2022 Nov; 85():104293. PubMed ID: 36182629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive proteomics and meta-analysis of COVID-19 host response.
    Babačić H; Christ W; Araújo JE; Mermelekas G; Sharma N; Tynell J; García M; Varnaite R; Asgeirsson H; Glans H; Lehtiö J; Gredmark-Russ S; Klingström J; Pernemalm M
    Nat Commun; 2023 Sep; 14(1):5921. PubMed ID: 37739942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction.
    Diorio C; Shraim R; Vella LA; Giles JR; Baxter AE; Oldridge DA; Canna SW; Henrickson SE; McNerney KO; Balamuth F; Burudpakdee C; Lee J; Leng T; Farrel A; Lambert MP; Sullivan KE; Wherry EJ; Teachey DT; Bassiri H; Behrens EM
    Nat Commun; 2021 Dec; 12(1):7222. PubMed ID: 34893640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
    Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
    Front Immunol; 2021; 12():700921. PubMed ID: 34539631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-resolution serum proteome trajectories in COVID-19 reveal patient-specific seroconversion.
    Geyer PE; Arend FM; Doll S; Louiset ML; Virreira Winter S; Müller-Reif JB; Torun FM; Weigand M; Eichhorn P; Bruegel M; Strauss MT; Holdt LM; Mann M; Teupser D
    EMBO Mol Med; 2021 Aug; 13(8):e14167. PubMed ID: 34232570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease.
    Ogata AF; Maley AM; Wu C; Gilboa T; Norman M; Lazarovits R; Mao CP; Newton G; Chang M; Nguyen K; Kamkaew M; Zhu Q; Gibson TE; Ryan ET; Charles RC; Marasco WA; Walt DR
    Clin Chem; 2020 Dec; 66(12):1562-1572. PubMed ID: 32897389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Machine learning-driven blood transcriptome-based discovery of SARS-CoV-2 specific severity biomarkers.
    Krishnamoorthy P; Raj AS; Kumar H
    J Med Virol; 2023 Feb; 95(2):e28488. PubMed ID: 36625381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies.
    Wu S; Xu Y; Zhang J; Ran X; Jia X; Wang J; Sun L; Yang H; Li Y; Fu B; Huang C; Liao P; Sun W
    Front Immunol; 2022; 13():893943. PubMed ID: 35958562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline characteristics and changes of biomarkers in disease course predict prognosis of patients with COVID-19.
    Li T; Wang X; Zhuang X; Wang H; Li A; Huang L; Zhang X; Xue Y; Wei F; Ma C
    Intern Emerg Med; 2021 Aug; 16(5):1165-1172. PubMed ID: 33565034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19.
    Battaglini D; Lopes-Pacheco M; Castro-Faria-Neto HC; Pelosi P; Rocco PRM
    Front Immunol; 2022; 13():857573. PubMed ID: 35572561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A predictive paradigm for COVID-19 prognosis based on the longitudinal measure of biomarkers.
    Chen X; Gao W; Li J; You D; Yu Z; Zhang M; Shao F; Wei Y; Zhang R; Lange T; Wang Q; Chen F; Lu X; Zhao Y
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19.
    Ravichandran S; Tang J; Grubbs G; Lee Y; Pourhashemi S; Hussaini L; Lapp SA; Jerris RC; Singh V; Chahroudi A; Anderson EJ; Rostad CA; Khurana S
    Nat Immunol; 2021 Nov; 22(11):1452-1464. PubMed ID: 34611361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative proteomics of hamster lung tissues infected with SARS-CoV-2 reveal host factors having implication in the disease pathogenesis and severity.
    Suresh V; Mohanty V; Avula K; Ghosh A; Singh B; Reddy RK; Parida D; Suryawanshi AR; Raghav SK; Chattopadhyay S; Prasad P; Swain RK; Dash R; Parida A; Syed GH; Senapati S
    FASEB J; 2021 Jul; 35(7):e21713. PubMed ID: 34105201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.